Literature DB >> 2685660

A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis.

L Lacomblez1, P Bouche, G Bensimon, V Meininger.   

Abstract

We performed a 3-month, double-blind, placebo-controlled trial of 300 mg of gangliosides (Cronassial) in 40 outpatients with amyotrophic lateral sclerosis (ALS). We evaluated drug effect through physical examinations and symptom scales. Though this dosage had no major toxic effect, Cronassial treatment did not significantly benefit ALS patients.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2685660     DOI： 10.1212/wnl.39.12.1635

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  12 in total

1.  Amyotrophic Lateral Sclerosis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis.

Authors:  O Blin; J Pouget; G Aubrespy; C Guelton; A Crevat; G Serratrice
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

Review 3.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Authors:  Robert G Miller; J D Mitchell; Dan H Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

Review 4.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

5.  The correlation between motor impairments and event-related desynchronization during motor imagery in ALS patients.

Authors:  Takashi Kasahara; Kentaro Terasaki; Yuki Ogawa; Junichi Ushiba; Harumichi Aramaki; Yoshihisa Masakado
Journal:  BMC Neurosci       Date:  2012-06-15       Impact factor: 3.288

6.  Pharmacological treatment for familial amyloid polyneuropathy.

Authors:  Francesca Magrinelli; Gian Maria Fabrizi; Lucio Santoro; Fiore Manganelli; Giampietro Zanette; Tiziana Cavallaro; Stefano Tamburin
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

7.  Bulbar impairment score and survival of stable amyotrophic lateral sclerosis patients after noninvasive ventilation initiation.

Authors:  Jesús Sancho; Daniel Martínez; Enric Bures; José Luis Díaz; Alejandro Ponz; Emilio Servera
Journal:  ERJ Open Res       Date:  2018-04-16

Review 8.  Clinical Measures of Bulbar Dysfunction in ALS.

Authors:  Yana Yunusova; Emily K Plowman; Jordan R Green; Carolina Barnett; Peter Bede
Journal:  Front Neurol       Date:  2019-02-19       Impact factor: 4.003

9.  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.

Authors:  Koji Abe; Yasuto Itoyama; Gen Sobue; Shoji Tsuji; Masashi Aoki; Manabu Doyu; Chikuma Hamada; Kazuoki Kondo; Takatomo Yoneoka; Makoto Akimoto; Hiide Yoshino
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-06       Impact factor: 4.092

Review 10.  Complex carbohydrates in drug development.

Authors:  R L Schnaar
Journal:  Adv Pharmacol       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.